Heather E. Wheeler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heather E. Wheeler has a total of 751 co-authors. Here are the top co-authors by number of shared publications:
- Hae Kyung Im
Department of Biological Chemistry, David Geffen School of Medicine, UCLA
57 shared publications - Ani Manichaikul
Department of Genome Sciences, University of Virginia School of Medicine, Charlottesville, USA
41 shared publications - Isabelle Gregga
Department of Biology, Loyola University Chicago, Chicago, Illinois
37 shared publications - Joellen M. Schildkraut
Emory University
35 shared publications - Paul David Peter Pharoah
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
35 shared publications - Siddhartha P. Kar
University of Cambridge
35 shared publications
Latest Publications
- Open Access
Systematic Integration of genomics with transcriptomics for the Study of Coronary Artery Disease and Subclinical Atherosclerosis
Introduction: Coronary artery disease (CAD) is a leading cause of death and disability worldwide. Although genome-wide association studies (GWAS) have identified over 300 loci associated with CAD risk, the molecular mechanisms linking these variants to disease and subclinical atherosclerosis are not fully understood. Methods: We performed integration of multi-ancestry CAD GWAS with transcriptomic data from the Multi-Ethnic Study of Atherosclerosis (MESA) obtained through the Trans-Omics for Precision Medicine (TOPMed) program. For integration, we applied Bayesian colocalization analysis with and without statistical fine-mapping to identify genes whose expression levels colocalize with CAD-associated loci. We further applied causal weighted gene co-expression network analysis (cWGCNA) to identify gene co-expression modules and key driver genes associated with subclinical atherosclerosis traits in MESA. Results: We identified 108 genes showing evidence of colocalization with CAD loci, including 24 shared between the two colocalization approaches and 48 novel genes not previously reported in CAD GWAS. Follow-up replication and validation analyses prioritized 5 novel (CCDC30, ZEB1-AS1, ZPR1, PLEKHJ1 and AC018816.3) and 8 previously reported genes (DHDDS, DDX59, LNPEP, DAGLA, ZKSCAN1, LIPA, OPRL1 and EIF2B2) with putative roles in both CAD and subclinical atherosclerosis. cWGCNA identified five gene modules significantly associated with subclinical atherosclerosis in MESA. Additionally, three key driver genes (ATG9B, PRAM1 and ZBTB46) identified by cWGCNA were also identified as CAD-colocalized genes. Discussion: Our integrative analysis highlights key genetic drivers and regulatory networks underlying CAD and subclinical atherosclerosis. These findings underscore the value of incorporating statistical fine-mapping in colocalization studies and demonstrate the utility of combining colocalization with co-expression network analysis to prioritize functional genes and pathways.
Open AccessSystematic Integration of genomics with transcriptomics for the Study of Coronary Artery Disease and Subclinical Atherosclerosis
Introduction: Coronary artery disease (CAD) is a leading cause of death and disability worldwide. Although genome-wide association studies (GWAS) have identified over 300 loci associated with CAD risk, the molecular mechanisms linking these variants to disease and subclinical atherosclerosis are not fully understood. Methods: We performed integration of multi-ancestry CAD GWAS with transcriptomic data from the Multi-Ethnic Study of Atherosclerosis (MESA) obtained through the Trans-Omics for Precision Medicine (TOPMed) program. For integration, we applied Bayesian colocalization analysis with and without statistical fine-mapping to identify genes whose expression levels colocalize with CAD-associated loci. We further applied causal weighted gene co-expression network analysis (cWGCNA) to identify gene co-expression modules and key driver genes associated with subclinical atherosclerosis traits in MESA. Results: We identified 108 genes showing evidence of colocalization with CAD loci, including 24 shared between the two colocalization approaches and 48 novel genes not previously reported in CAD GWAS. Follow-up replication and validation analyses prioritized 5 novel (CCDC30, ZEB1-AS1, ZPR1, PLEKHJ1 and AC018816.3) and 8 previously reported genes (DHDDS, DDX59, LNPEP, DAGLA, ZKSCAN1, LIPA, OPRL1 and EIF2B2) with putative roles in both CAD and subclinical atherosclerosis. cWGCNA identified five gene modules significantly associated with subclinical atherosclerosis in MESA. Additionally, three key driver genes (ATG9B, PRAM1 and ZBTB46) identified by cWGCNA were also identified as CAD-colocalized genes. Discussion: Our integrative analysis highlights key genetic drivers and regulatory networks underlying CAD and subclinical atherosclerosis. These findings underscore the value of incorporating statistical fine-mapping in colocalization studies and demonstrate the utility of combining colocalization with co-expression network analysis to prioritize functional genes and pathways.
- 16 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6808) , eadx2989
Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed
Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.
- 16 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6808) , eadx2989
Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed
Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.
- Open Access
Multi-ancestry modeling improves fine-mapping resolution, protein prediction, and discovery for proteome-wide association studies
Proteomic predictive models are predominantly trained on cis-acting variants in European-ancestry cohorts, limiting power and predictive accuracy in ancestrally diverse populations. We performed cis - and trans -protein quantitative trait locus (pQTL) mapping and developed protein-prediction models using whole-genome sequencing (WGS) and plasma protein levels (Olink) across four ancestry groups from the Trans-omics for Precision Medicine (TOPMed) Multi-Ethnic Study of Atherosclerosis (MESA): European (EUR, n=1270), African (AFR, n=675), Hispanic (HIS, n=642), and Chinese (CHN, n=366), and a combined population (ALL, n=2953). African-ancestry samples demonstrated improved fine-mapping resolution relative to cohort size, yielding significantly smaller cis-credible sets than European-ancestry samples, consistent with shorter linkage disequilibrium (LD) blocks and greater allele frequency diversity in African-ancestry populations. For the first time, we benchmarked fine-mapping models SuSiE, SuShiE, MultiSuSiE, and SuSiEx with multi-ancestral cohorts, revealing a precision-recall tradeoff driven by model assumptions. Comparing protein-prediction models, multivariate adaptive shrinkage (MASHR) and ultimate deconvolution in R (UDR) outperformed elastic net (EN) regression, with trans -pQTL inclusion and fine-mapping improving prediction performance and proteome-wide association study (PWAS) discovery. Applying our models in PWAS of 10 phenotypes, we discovered 68 protein-phenotype associations in All of Us (AoU) that also replicated in Pan-UK Biobank. MASHR and UDR models identified 60% more protein-phenotype associations than EN. Notably, 32 of these associations were not previously reported in the GWAS Catalog. Overall, our study demonstrates the importance of including multiple ancestries in genomic studies to capture the full spectrum of regulatory variation and improve cross-ancestry generalizability.
Open AccessMulti-ancestry modeling improves fine-mapping resolution, protein prediction, and discovery for proteome-wide association studies
Proteomic predictive models are predominantly trained on cis-acting variants in European-ancestry cohorts, limiting power and predictive accuracy in ancestrally diverse populations. We performed cis - and trans -protein quantitative trait locus (pQTL) mapping and developed protein-prediction models using whole-genome sequencing (WGS) and plasma protein levels (Olink) across four ancestry groups from the Trans-omics for Precision Medicine (TOPMed) Multi-Ethnic Study of Atherosclerosis (MESA): European (EUR, n=1270), African (AFR, n=675), Hispanic (HIS, n=642), and Chinese (CHN, n=366), and a combined population (ALL, n=2953). African-ancestry samples demonstrated improved fine-mapping resolution relative to cohort size, yielding significantly smaller cis-credible sets than European-ancestry samples, consistent with shorter linkage disequilibrium (LD) blocks and greater allele frequency diversity in African-ancestry populations. For the first time, we benchmarked fine-mapping models SuSiE, SuShiE, MultiSuSiE, and SuSiEx with multi-ancestral cohorts, revealing a precision-recall tradeoff driven by model assumptions. Comparing protein-prediction models, multivariate adaptive shrinkage (MASHR) and ultimate deconvolution in R (UDR) outperformed elastic net (EN) regression, with trans -pQTL inclusion and fine-mapping improving prediction performance and proteome-wide association study (PWAS) discovery. Applying our models in PWAS of 10 phenotypes, we discovered 68 protein-phenotype associations in All of Us (AoU) that also replicated in Pan-UK Biobank. MASHR and UDR models identified 60% more protein-phenotype associations than EN. Notably, 32 of these associations were not previously reported in the GWAS Catalog. Overall, our study demonstrates the importance of including multiple ancestries in genomic studies to capture the full spectrum of regulatory variation and improve cross-ancestry generalizability.
- Open Access
Integration of dilated cardiomyopathy genomics with transcriptomics from the human heart implicates regulatory molecular mechanisms
Heart failure (HF) is a leading global cause of morbidity and mortality, yet the regulatory molecular mechanisms that link genetic variation to cardiac dysfunction remain elusive. To bridge this gap, we created the Trans-Omics for Precision Medicine in Congestive Heart Failure (TOPCHeF) resource, a multi-omics dataset comprising >700 human left-ventricular tissue samples, including dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM), and non-failing controls, with paired whole-genome and RNA sequencing. By mapping expression- (eQTL) and splicing- (sQTL) quantitative trait loci directly in diseased human hearts, we identified over 10,000 transcripts with significant eQTL and 8,600 isoforms with significant sQTL, across both coding and non-coding genes, many of which overlap loci previously associated with HF and emerging novel gene associations. Single-locus colocalization with a largescale DCM genome-wide association study revealed 21 expression and 17 splicing-QTL that share causal variants with disease risk. These include known Mendelian cardiomyopathy risk genes such as FLNC and ACTN2, and novel regulatory candidates like CAMK2D, LMF1, MYOZ1, SKI, SYNPO2L, and TKT. Several loci also showed coordinated effects on both gene expression and RNA splicing, implicating calcium signaling, cytoskeletal organization, and metabolic pathways in HF pathogenesis. Together, these results help define the regulatory landscape of the failing human heart and establish TOPCHeF as a foundational resource for connecting genetic variation to transcriptional and splicing molecular mechanisms in HF research.
Open AccessIntegration of dilated cardiomyopathy genomics with transcriptomics from the human heart implicates regulatory molecular mechanisms
Heart failure (HF) is a leading global cause of morbidity and mortality, yet the regulatory molecular mechanisms that link genetic variation to cardiac dysfunction remain elusive. To bridge this gap, we created the Trans-Omics for Precision Medicine in Congestive Heart Failure (TOPCHeF) resource, a multi-omics dataset comprising >700 human left-ventricular tissue samples, including dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM), and non-failing controls, with paired whole-genome and RNA sequencing. By mapping expression- (eQTL) and splicing- (sQTL) quantitative trait loci directly in diseased human hearts, we identified over 10,000 transcripts with significant eQTL and 8,600 isoforms with significant sQTL, across both coding and non-coding genes, many of which overlap loci previously associated with HF and emerging novel gene associations. Single-locus colocalization with a largescale DCM genome-wide association study revealed 21 expression and 17 splicing-QTL that share causal variants with disease risk. These include known Mendelian cardiomyopathy risk genes such as FLNC and ACTN2, and novel regulatory candidates like CAMK2D, LMF1, MYOZ1, SKI, SYNPO2L, and TKT. Several loci also showed coordinated effects on both gene expression and RNA splicing, implicating calcium signaling, cytoskeletal organization, and metabolic pathways in HF pathogenesis. Together, these results help define the regulatory landscape of the failing human heart and establish TOPCHeF as a foundational resource for connecting genetic variation to transcriptional and splicing molecular mechanisms in HF research.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S5. PhenomeXcan TWAS results for 8 genes that had cancer associations.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S5. PhenomeXcan TWAS results for 8 genes that had cancer associations.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S1. Summary statistics of 7 cancer types tested with ARIC plasma proteome models, FDR<0.05, with single- and multi-variant COLOC results.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S1. Summary statistics of 7 cancer types tested with ARIC plasma proteome models, FDR<0.05, with single- and multi-variant COLOC results.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S3. PWAS meta-FDR<0.05 proteins with ovarian cancer associations.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S3. PWAS meta-FDR<0.05 proteins with ovarian cancer associations.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S4. PWAS meta-FDR<0.05 proteins with endometrial cancer associations.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S4. PWAS meta-FDR<0.05 proteins with endometrial cancer associations.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S2. Replication of cancer PWAS results in independent cohort with meta-analysis FDR<0.05.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Table S2. Replication of cancer PWAS results in independent cohort with meta-analysis FDR<0.05.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Supplementary Figure S1: Workflow illustrating the methods.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
Supplementary Figure S1: Workflow illustrating the methods.